Legend Biotech Corp Cash Flows From Used In Investing Activities
Legend Biotech Corp (LEGN) reported Cash Flows From Used In Investing Activities of $709.60 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Cash Flow › Investing Activities
ifrs-full:CashFlowsFromUsedInInvestingActivities · last filed 2026-03-10
- Legend Biotech Corp cash flows from used in investing activities for the quarter ending 2025-12-31 was $638.49M.
- Legend Biotech Corp cash flows from used in investing activities for the quarter ending 2025-09-30 was -$20.00M, a 106.08% decline year-over-year.
- Legend Biotech Corp cash flows from used in investing activities for the quarter ending 2025-06-30 was -$165.53M.
- Legend Biotech Corp cash flows from used in investing activities for the quarter ending 2025-03-31 was $256.64M.
| Period end | Cash Flows From Used In Investing Activities 3 month | Cash Flows From Used In Investing Activities 6 month | Cash Flows From Used In Investing Activities 9 month | Cash Flows From Used In Investing Activities 12 month | Cash Flows From Used In Investing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $638.49M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $618.49M derived: sum of 2 quarters · filed 2026-03-10 | $452.96M derived: sum of 3 quarters · filed 2026-03-10 | $709.60M 20-F · filed 2026-03-10 | |
| 2025-09-30 | -$20.00M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | -$185.53M derived: sum of 2 quarters · filed 2025-11-12 | $71.11M 6-K · filed 2025-11-12 | -$16.78M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-06-30 | -$165.53M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | $91.11M 6-K · filed 2025-08-11 | $3.22M derived: sum of 3 quarters · filed 2026-03-10 | $332.29M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-03-31 | $256.64M 6-K · filed 2025-05-13 | $168.74M derived: sum of 2 quarters · filed 2026-03-10 | $497.82M derived: sum of 3 quarters · filed 2026-03-10 | -$197.81M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-12-31 | -$87.90M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $241.18M derived: sum of 2 quarters · filed 2026-03-10 | -$454.45M derived: sum of 3 quarters · filed 2026-03-10 | -$850.60M 20-F · filed 2026-03-10 | -$850.54M 20-F · filed 2025-03-11 |
| 2024-09-30 | $329.08M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | -$366.55M derived: sum of 2 quarters · filed 2025-11-12 | -$762.70M 6-K · filed 2025-11-12 | -$355.08M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-06-30 | -$695.63M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | -$1.09B 6-K · filed 2025-08-11 | -$684.16M derived: sum of 3 quarters · filed 2026-03-10 | -$893.23M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-03-31 | -$396.15M 6-K · filed 2025-05-13 | $11.47M derived: sum of 2 quarters · filed 2026-03-10 | -$197.60M derived: sum of 3 quarters · filed 2026-03-10 | -$319.28M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2023-12-31 | $407.62M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $198.55M derived: sum of 2 quarters · filed 2026-03-10 | $76.87M derived: sum of 3 quarters · filed 2026-03-10 | $92.90M 20-F · filed 2026-03-10 | $92.79M 20-F · filed 2024-03-19 |
| 2023-09-30 | -$209.07M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | -$330.75M derived: sum of 2 quarters · filed 2024-11-12 | -$314.72M 6-K · filed 2024-11-12 | -$289.79M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | -$121.68M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | -$105.65M 6-K · filed 2024-08-09 | -$80.72M derived: sum of 3 quarters · filed 2025-03-11 | $47.17M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-03-31 | $16.03M 6-K · filed 2024-05-13 | $40.96M derived: sum of 2 quarters · filed 2025-03-11 | $168.85M derived: sum of 3 quarters · filed 2025-03-11 | ||
| 2022-12-31 | $24.93M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | $152.82M derived: sum of 2 quarters · filed 2025-03-11 | -$77.09M 20-F · filed 2025-03-11 | ||
| 2022-09-30 | $127.89M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | -$102.02M 6-K · filed 2023-11-20 | |||
| 2022-06-30 | -$229.91M 6-K · filed 2023-08-15 | ||||
| 2021-12-31 | -$194.98M 20-F · filed 2024-03-19 | ||||
| 2021-06-30 | -$185.82M 6-K · filed 2021-08-23 | ||||
| 2020-12-31 | -$24.17M 20-F · filed 2023-03-30 | ||||
| 2020-06-30 | -$26.71M 6-K · filed 2021-08-23 | ||||
| 2019-12-31 | -$58.65M 20-F/A · filed 2023-02-17 | ||||
| 2018-12-31 | -$102.26M 20-F · filed 2021-04-02 |